What Vicebio does

Vicebio was a UK-based biopharmaceutical company founded in 2019 that developed next-generation respiratory virus vaccines using the Molecular Clamp technology platform, licensed exclusively from the University of Queensland. The company's core technology stabilizes viral surface proteins in their prefusion state to elicit stronger immune responses, and Vicebio was the only company advancing this second-generation platform following earlier setbacks that caused false-positive HIV test results in prior applications. Its lead asset, VXB-241, is a bivalent vaccine candidate targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), which had advanced into first-in-human clinical trials with interim data expected by mid-2025.

Vicebio operated as a pre-revenue, development-stage biotech with no commercial products and no disclosed pricing model. Revenue mechanics were tied to future vaccine commercialization (targeting healthcare providers and public health systems globally) rather than current sales; the company's economic value lay in clinical pipeline progression and the underlying Molecular Clamp platform IP. Go-to-market activity was conducted through scientific publications, clinical trial execution, and pharmaceutical industry partnerships rather than traditional sales channels. The company was venture-backed, with a $100M Series B closed in September 2024 led by TCGX alongside Goldman Sachs Alternatives, Avoro Ventures, venBio, UniQuest, and founding investor Medicxi.

In July 2025, Sanofi announced its acquisition of Vicebio for up to $1.6 billion ($1.15B upfront plus up to $450M in milestones), and completed the transaction on December 4, 2025, making Vicebio a wholly-owned subsidiary and representing the largest acquisition of a company commercializing IP from an Australian university. Leadership at the time of acquisition included Emmanuel Hanon (CEO), Giovanni Della Cioppa (CMO), Koen Huygens (CQO), and Jean Smal (CTO).

Name

Vicebio

Legal name

Vicebio

Website

https://vicebio.com

Company type

Private

Founded year

2019

Operating status

Acquired

Headcount range

11–50 employees

Short description

Vicebio was a UK-based, pre-revenue biopharmaceutical company developing next-generation respiratory virus vaccines using the Molecular Clamp technology platform licensed from the University of Queensland. Its lead candidate, VXB-241, targets RSV and hMPV, and the company was acquired by Sanofi in December 2025.

Ownership category

akta.pro rank

Product category

Respiratory Vaccines

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD)

akta.pro secondary industry

Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens) (HLAAAEAC)

Keywords

• Respiratory virus vaccines
• Molecular clamp technology
• Vaccine development
• Biopharmaceutical research
• Multivalent vaccines

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Others

Core offering

Vicebio is a clinical-stage biopharmaceutical company developing next-generation respiratory virus vaccines using its proprietary Molecular Clamp technology platform, which stabilizes viral surface proteins in their prefusion state. The lead candidate, VXB-241, is a bivalent vaccine targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), and was advancing through first-in-human clinical trials prior to the company's acquisition.

Product overview

Vicebio is an early-stage vaccine developer focused on respiratory viruses. The company utilizes a Molecular Clamp technology platform to develop multivalent vaccine candidates. Its lead product candidate is VXB-241, a bivalent vaccine targeting RSV and hMPV, which was in first-in-human trials. The company was acquired by Sanofi in December 2025.

Differentiator

Problem solved

Functional benefit

Brands

• VXB-241: Bivalent vaccine candidate targeting RSV and hMPV respiratory viruses, developed using Molecular Clamp technology, in first-in-human trials

Products and services

• Molecular Clamp Technology Platform Proprietary vaccine antigen-stabilization platform that locks viral surface glycoproteins in their prefusion state to enable design of recombinant subunit vaccines against respiratory viruses. Licensed from the University of Queensland and used as the foundational technology for Vicebio's pipeline.
• VXB-241 Bivalent vaccine candidate targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), built on the Molecular Clamp platform. Advanced into first-in-human clinical trials as Vicebio's lead clinical asset.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Two partnerships are on record, tiered core.

• SanoficoreStrategic or Co-development Partner · 4 December 2025Sanofi completed acquisition of Vicebio on December 4, 2025, adding a respiratory virus vaccine candidate and expanding Sanofi's capabilities in vaccine design, particularly involving its Molecular Clamp technology. Deal valued at $1.6 billion including $1.15 billion upfront and up to $450 million in milestone payments.
• University of QueenslandcoreTechnology or Integration · 22 July 2025Vicebio licensed the Molecular Clamp vaccine technology from the University of Queensland. The deal represented the largest acquisition of a company commercializing intellectual property from an Australian university, validating 12 years of UQ research. UQ continues using the technology for pandemic preparedness research in collaboration with CEPI.

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Emerging players

• Arcturus Therapeutics: Arcturus Therapeutics develops self-amplifying mRNA vaccines targeting COVID-19, influenza, and RSV. With RSV-targeted candidates in development, Arcturus is an emerging peer competing in the same respiratory virus indication space as Vicebio using alternative nucleic acid-based technology.
• Blue Lake Biotechnology: Blue Lake Biotechnology develops intranasal parainfluenza virus 5 (PIV5)-vectored vaccines for RSV and other respiratory pathogens. As a small emerging vaccine company focused on the same respiratory virus targets, it represents an emerging peer with overlapping scientific and indication focus.
• Meissa Vaccines: Meissa Vaccines is an early-stage company developing live-attenuated intranasal vaccines targeting RSV and other respiratory viruses. It shares Vicebio's focus on respiratory virus vaccine innovation but uses a different technological approach, making it an emerging peer in the same indication space.

Broad incumbents

• Novavax: Novavax is a vaccine developer using recombinant protein nanoparticle technology for influenza and COVID-19 vaccines, with adjuvanted approaches comparable to Vicebio's protein-subunit platform. As a broader vaccine incumbent with overlapping technology and respiratory indication focus, it represents an adjacent competitor in protein-based vaccine development.
• Pfizer: Pfizer markets Abrysvo, an approved RSV vaccine, and has extensive respiratory vaccine infrastructure. As a broad incumbent pharmaceutical company with overlapping vaccine capabilities, Pfizer competes with Vicebio's lead candidate in the same therapeutic area while having vastly greater commercial scale.
• GSK: GSK markets Arexvy, the first approved RSV vaccine for older adults, and has deep vaccine R&D and commercial capabilities. As a major vaccine incumbent with overlapping respiratory pathogen programs, GSK competes directly with Vicebio's bivalent RSV/hMPV candidate.

Direct peers

• Moderna: Moderna is a leading mRNA vaccine developer with an approved RSV vaccine (mResvia) targeting the same respiratory virus space as Vicebio's VXB-241. Both companies compete in next-generation respiratory virus vaccine development, though Moderna uses mRNA while Vicebio uses a protein-subunit stabilization approach.
• Bavarian Nordic: Bavarian Nordic is developing MVA-BN RSV, a modified vaccinia Ankara-based RSV vaccine in late-stage clinical development. As a smaller specialty vaccine company focused on respiratory pathogens, it competes with Vicebio for clinical and commercial positioning in the RSV vaccine market.
• Icosavax: Icosavax developed VLP (virus-like particle) based vaccines targeting RSV and hMPV, the same two pathogens as Vicebio's VXB-241. The company was acquired by AstraZeneca in 2024, validating strategic interest in bivalent respiratory virus vaccines and making it a directly comparable technology and indication peer.

Others

• Sanofi: Sanofi acquired Vicebio in December 2025 for up to $1.6B and is now Vicebio's parent company. While not a peer in the traditional sense, Sanofi's broader vaccine franchise (including Fluzone, Beyfortus for RSV prevention in infants) provides the commercialization platform for Vicebio's Molecular Clamp candidates.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/vicebio

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds1 record

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vicebio